Free
Pain Medicine  |   August 2004
Delta-opioid Agonist SNC80 Can Attenuate the Development of Dynorphin A-induced Tactile Allodynia in Rats
Author Affiliations & Notes
  • Yoshitaka Kawaraguchi, M.D.
    *
  • Masahiko Kawaguchi, M.D.
  • Masahiro Takahashi, M.D.
  • Toshinori Horiuchi, M.D.
  • Takanori Sakamoto, M.D.
  • Hitoshi Furuya, M.D.
    §
  • *Staff Anesthesiologist, †Assistant Professor, ‡Research Fellow, §Professor and Chair.
Article Information
Pain Medicine
Pain Medicine   |   August 2004
Delta-opioid Agonist SNC80 Can Attenuate the Development of Dynorphin A-induced Tactile Allodynia in Rats
Anesthesiology 8 2004, Vol.101, 546-549. doi:
Anesthesiology 8 2004, Vol.101, 546-549. doi:
DYNORPHIN A is an endogenous opioid peptide with a high degree of selectivity for κ-opioid receptors. It has been reported that high dosages or sustained exposure of dynorphin A may cause neurologic dysfunction including hyperalgesia, allodynia,1–3 and paralysis.4 There is also considerable evidence that levels of dynorphin A increase significantly at the sites of spinal cord injuries5 and in the spinal cord after nerve injury,6,7 and the increase of dynorphin levels in the spinal cord was associated with neurologic dysfunction.8 As neuropathic pain remains a devastating sequela after spinal cord trauma and nerve injury, further understanding regarding pathophysiological mechanisms and treatment of dynorphin-induced behavioral dysfunction may become a key for strategies of pain managements in such patients.
Recent evidence suggested the antinociceptive effects of δ-opioid agonists in a variety of pain models.9,10 SNC80, (+)-4-[(αR)-α((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3 -methoxybenzyl-N,N -diethylbenzamide, is a highly selective nonpeptidic delta opioid agonist. Although peptidic opioids may rapidly degrade, nonpeptidic opioids are proteolytically stable and have enhanced bioavailability relative to the peptidic opioids.11,12 Although several investigators have demonstrated the antinociceptive effects of SNC80 in chronic pain models,12,13 there has been no data on its antiallodynic effect. We hypothesized that δ-opioid agonist SNC80 can attenuate dynorphin A-induced tactile allodynia. First, to determine the dosage of dynorphin and time course of dynorphin-induced allodynia, dose–dependent effects of intrathecally administered dynorphin on the tactile allodynia were evaluated. Second, the effect of N  -methyl-d-aspartate receptor antagonist MK801 on dynorphin-induced tactile allodynia was assessed. Finally, the effects of SNC80 on dynorphin A-induced tactile allodynia were investigated.
Materials and Methods
The Animal Experiment Committee of Nara Medical University approved this study. All experimental procedures were performed in accordance with the guidelines established in the Guide for the Care and Use of Laboratory Animals available from the National Academy of Science (Washington, DC).
Animals
Male Sprague-Dawley rats (300–350 g; Japan SLC, Shizuoka, Japan) were housed in cages with 12–24h light-dark cycle and were allowed free access to food and water.
Drugs
Dynorphin A(1-13) (Biogenesis Ltd, Poole, England) and MK801 (EMD Biosciences Inc. San Diego, CA) were dissolved in saline, 0.9%. SNC80 (ALEXIS Biochemicals, Lausanne, Switzerland) was prepared in its vehicle (saline, 0.9%, and 100 mm HCl).
Intrathecal Catheter Implantation
Under isoflurane anesthesia (2% in oxygen-air), the rats were implanted catheters according to the method described by Yaksh and Rudy.14 A PE-10 polyethylene tube (8.5 cm) was inserted through the atlanto-occipital membrane and to the lumbar enlargement.
Nociceptive Behavioral Testing
Mechanical allodynia was determined by measuring the paw withdrawal in response to probing with von Frey filaments. A 50% withdrawal threshold was determined by increasing and decreasing stimulus strength eliciting paw withdrawal and estimating the paw withdrawal threshold by a Dixon nonparametric test.15 Rats with a baseline threshold less than 10 g were excluded from this study.
Experimental Protocol
Rats were allowed 7 days to recover from the intrathecal implantation, and any rats exhibiting motor deficiency were discarded from testing. We measured the baseline paw withdrawal threshold (control value). In our preliminary study, we demonstrated that even 5 nmol of intrathecal dynorphin A (1-13) produced transient hind limb paralysis in some animals, resulting in a failure of behavioral assessment. Therefore, we used lower doses of dynorphin less than 5 nmol. In the first study, the rats were randomly allocated to one of four groups. Animals received saline (group S; n = 8) or dynorphin A (1-13) 0.25 nmol (group D0.25; n = 7), 1 nmol (group D1; n = 9), or 2 nmol (group D2; n = 7). All drugs were injected intrathecally in a volume of 5 μl followed by a 9-μl flush.14 In a single blind manner, that is, the observer had no information as to the group designation, we measured paw withdrawal threshold at 10 min, 30 min, 1 h, 2 h, 4 h, 8 h, 1 day, 3 days, and 7 days after intrathecal injection. In the second study, rats were randomly allocated to one of three groups (n = 7 in each group). In the groups M5 and M10, 5 nmol or 10 nmol of MK801, respectively, was intrathecally administered 20 min before intrathecal injection of 2 nmol of dynorphin A (1-13). In the group S, saline was intrathecally administered. In study 3, the rats were randomly allocated to one of three groups (n = 9 in each group). In the groups S25 and S100, 25 nmol or 100 nmol of SNC80, respectively, was intrathecally administered 20 min before intrathecal injection of 2 nmol of dynorphin A (1-13). In the group S, saline with 100 mm HCl was intrathecally administered. In studies 2 and 3, an observer blinded to the drug applications measured paw withdrawal threshold at 10 min, 30 min, 1 h, 2 h, 4 h, and 8 h after intrathecal injection of dynorphin.
Statistics
All data are expressed as mean ± SEM. Statistical analysis was performed using two-way analysis of variance with repeated measurements followed by Student-Newman-Keuls test for multiple comparisons. A P  value of <0.05 was considered statistically significant.
Results
Dynprphin-Induced Tactile Allodynia
As the withdrawal thresholds of left and right hind paws were similar in each group, mean values of the bilateral thresholds were used for further analysis. As shown in figure 1, the intrathecal administration of 2 nmol of dynorphin A (1-13) produced a significant reduction of the withdrawal threshold at 10 min, 30 min, and 1 h after injection compared with the control values and paw withdrawal threshold at 30 min and 1 h after injection was significantly lower than in the group S. The intrathecal administration of 1 nmol of dynorphin A (1-13) also produced a significant reduction in the withdrawal threshold at 30 min, 1 h, and 2 h after injection compared with the control values and paw withdrawal threshold at 30 min, 1 h, 2 h, and 4 h after injection was significantly lower than in the group S.
Fig. 1. Time-response curves for tactile allodynia induced by intrathecal injections of dynorphin A (1-13). Saline, 0.9%,(group S; closed circle, n = 8), 0.25 nmol of dynorphin (group D0.25; triangle, n = 7), 1 nmol of dynorphin (group D1; square, n = 9), or 2 nmol of dynorphin (group D2; open circle, n = 7) was intrathecally administered and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
Fig. 1. Time-response curves for tactile allodynia induced by intrathecal injections of dynorphin A (1-13). Saline, 0.9%,(group S; closed circle, n = 8), 0.25 nmol of dynorphin (group D0.25; triangle, n = 7), 1 nmol of dynorphin (group D1; square, n = 9), or 2 nmol of dynorphin (group D2; open circle, n = 7) was intrathecally administered and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
Fig. 1. Time-response curves for tactile allodynia induced by intrathecal injections of dynorphin A (1-13). Saline, 0.9%,(group S; closed circle, n = 8), 0.25 nmol of dynorphin (group D0.25; triangle, n = 7), 1 nmol of dynorphin (group D1; square, n = 9), or 2 nmol of dynorphin (group D2; open circle, n = 7) was intrathecally administered and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
×
Effect of MK801 on Dynorphin-Induced Tactile Allodynia
Changes in withdrawal thresholds after 2 nmol of dynorphin intrathecal injection with or without MK-801 pretreatment are shown in figure 2. Rats pretreated with saline elicited a significant reduction in the withdrawal threshold at 10 min and 30 min after injection. Pretreatment with 5 or 10 nmol of MK801 failed to elicit a significant reduction in the withdrawal threshold compared with the control values. Furthermore, withdrawal thresholds at 10 min and 30 min after injection in the group M10 and at 30 min in the group M5 were significantly higher than in the group S.
Fig. 2. Effect of MK801 on 2 nmol of dynorphin A (1-13)-induced tactile allodynia. Saline, 0.9%, (group S; circle, n = 7), 10 nmol of MK801 (group M10; triangle, n = 7), or 5 nmol of MK801(group M5; square, n = 7) was intrathecally administered 20 min before intrathecal injection of 2 nmol of dynorphin A (1-13), and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
Fig. 2. Effect of MK801 on 2 nmol of dynorphin A (1-13)-induced tactile allodynia. Saline, 0.9%, (group S; circle, n = 7), 10 nmol of MK801 (group M10; triangle, n = 7), or 5 nmol of MK801(group M5; square, n = 7) was intrathecally administered 20 min before intrathecal injection of 2 nmol of dynorphin A (1-13), and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
Fig. 2. Effect of MK801 on 2 nmol of dynorphin A (1-13)-induced tactile allodynia. Saline, 0.9%, (group S; circle, n = 7), 10 nmol of MK801 (group M10; triangle, n = 7), or 5 nmol of MK801(group M5; square, n = 7) was intrathecally administered 20 min before intrathecal injection of 2 nmol of dynorphin A (1-13), and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
×
Effect of SNC80 on Dynorphin-Induced Tactile Allodynia
Changes in withdrawal thresholds after 2 nmol of dynorphin intrathecal injection with or without SNC80 pretreatment are shown in figure 3. Rats pretreated with saline with 100 mm HCl elicited a significant reduction in the withdrawal threshold at 10 min, 30 min, and 1 h after injection. In the group S25, withdrawal thresholds were significantly reduced at 30 min after injection. In the group S100, withdrawal thresholds remained unchanged during the observation period. Withdrawal thresholds at 10 min, 30 min and 1 h after dynorphin injection were significantly higher in the group S100 compared with those in the group S.
Fig. 3. Effect of SNC80 on 2 nmol of dynorphin A (1-13)-induced tactile allodyniaSaline, 0.9%,with 100 mm HCl (group S; circle, n = 9) or 100 nmol of SNC80 (group S100; triangle, n = 9), or 25 nmol of SNC80 (group S25; square, n = 9) was intrathecally administered 20 min before intrathecal injection of 2 nmol of dynorphin, and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
Fig. 3. Effect of SNC80 on 2 nmol of dynorphin A (1-13)-induced tactile allodyniaSaline, 0.9%,with 100 mm HCl (group S; circle, n = 9) or 100 nmol of SNC80 (group S100; triangle, n = 9), or 25 nmol of SNC80 (group S25; square, n = 9) was intrathecally administered 20 min before intrathecal injection of 2 nmol of dynorphin, and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
Fig. 3. Effect of SNC80 on 2 nmol of dynorphin A (1-13)-induced tactile allodyniaSaline, 0.9%,with 100 mm HCl (group S; circle, n = 9) or 100 nmol of SNC80 (group S100; triangle, n = 9), or 25 nmol of SNC80 (group S25; square, n = 9) was intrathecally administered 20 min before intrathecal injection of 2 nmol of dynorphin, and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
×
Discussion
This study shows that intrathecally administered dynorphin A (1-13) produced transient tactile allodynia and pretreatment with MK-801 or SNC80 dose-dependently attenuated the development of tactile allodynia induced by dynorphin A.
As reported previously,1–3 intrathecal administration of dynorphin A produced tactile allodynia. Dynorphin-induced allodynia peaked at 30 min after injection, but lasted for only a short period. These findings are in contrast to the results in the previous study.1,2 Vandrah et al.  1 reported that intrathecal administration of dynorphin A produced a significant long-lasting tactile allodynia up to 60 days after injection. The reasons of these contradictory results are unknown. However, the dosage of dynorphin might have affected the results.
The mechanisms by which intrathecal administration of dynorphin induces tactile allodynia are unknown. Several possible explanations are as follows. First, dynorphin-induced allodynia may be attributable to ischemic injury after the reduction of spinal cord blood flow.16 Second, N  -methyl-d-aspartate receptors may be involved in the development of tactile allodynia after intrathecal administration of dynorphin A.1–3 In fact, we confirmed that dynorphin-induced allodynia could be reversed by pretreatment with N  -methyl-d-aspartate antagonist MK-801 in the present study.
Although the classic view has been that neuropathic pain is resistant to opioid therapy, recent evidence suggested an important role of delta opioid receptor agonists in antinociception at the level of the spinal cord.9,10 These findings were compatible with the results in the present study, in which SNC80 attenuated tactile allodynia. The mechanisms of antiallodynic effect of intrathecally administered SNC80 observed in the present study are unknown. However, glutamate- and glutamate receptor-mediated responses might be at least involved in antiallodynic effect of SNC80. Zhang et al.  17 demonstrated that delta opioid receptor agonist, [D-Ala2, D-Leu5]-enkephalin (DADLE), reduced glutamate-induced excitotoxic injury. Wang et al.  18 reported that δ-opioid agonist, [D-Phe2, D-Phe5]-enkephalin (DPDPE) attenuated N  -methyl-d-aspartate-evoked responses of nociceptive neurons. In fact, N  -methyl-d-aspartate receptor antagonists have been shown to attenuate antinociception induced by δ-opioid receptor agonists.19,20 Considering that dynorphin-induced allodynia was at least in part mediated through the N  -methyl-d-aspartate receptor activation, SNC80 might exert antiallodynic effects by inhibiting glutamate- and N  -methyl-d-aspartate-mediated responses in this model. Further investigations would be required to clarify the exact mechanisms of antiallodynic effect of SNC80.
The authors thank Osamu Kakinohana, Ph.D. (Assistant Project Scientist, Department of Anesthesiology, University of California, San Diego, San Diego, California), Joho Tokumine, M.D. (Assistant Professor, Department of Anesthesiology, University of the Ryukyus, Okinawa, Japan), and Tomoki Nishiyama, M.D. (Associate Professor, Department of Anesthesiology, The University of Tokyo, Tokyo, Japan) for their support in preparing the animal model.
References
Vanderah TW, Laughlin T, Lashbrook JM, Nichols ML, Wilcox GL, Ossipov MH, Malan TP, Porreca F: Single intrathecal injections of dynorphin A or des-Try-dynorphins produce long-lasting allodynia in rats: Blockade by MK-801 but not naloxone. Pain 1996; 68:275–81Vanderah, TW Laughlin, T Lashbrook, JM Nichols, ML Wilcox, GL Ossipov, MH Malan, TP Porreca, F
Laughlin TM, Vanderah TW, Lashbrook J, Nichols ML, Ossipov M, Porreca F, Wilcox GL: Spinally administered dynorphin A produces long-lasting allodynia: Involvement of NMDA but not opioid receptors. Pain 1997; 72:253–60Laughlin, TM Vanderah, TW Lashbrook, J Nichols, ML Ossipov, M Porreca, F Wilcox, GL
Tan-No K, Esashi A, Nakagawasai O, Niijima F, Tadano T, Sakurada C, Sakurada T, Bakalkin G, Terenius L, Kisara K: Intrathecally administered big dynorphin, a prodynorphin-derived peptide, produces nociceptive behavior through an N  -methyl-d-aspartate receptor mechanism. Brain Res 2002; 952:7–14Tan-No, K Esashi, A Nakagawasai, O Niijima, F Tadano, T Sakurada, C Sakurada, T Bakalkin, G Terenius, L Kisara, K
Long JB, Petras JM, Mobley WC, Holaday JW: Neurological dysfunction after intrathecal injection of dynorphin A (1-13) in the rat. II. Nonopioid mechanisms mediate loss of motor, sensory and autonomic function. J Pharmacol Exp Ther 1988; 246:1167–74Long, JB Petras, JM Mobley, WC Holaday, JW
Cox BM, Molineaux CJ, Jacobs TP, Rosenberger JG, Faden AI: Effects of traumatic injury on dynorphin immunoreactivity in spinal cord. Neuropeptides 1985; 5:571–4Cox, BM Molineaux, CJ Jacobs, TP Rosenberger, JG Faden, AI
Draisci G, Kajander KC, Dubner R, Bennett GJ, Iadarola MJ: Up-regulation of opioid gene expression in spinal cord evoked by experimental nerve injuries and inflammation. Brain Res 1991; 560:186–92Draisci, G Kajander, KC Dubner, R Bennett, GJ Iadarola, MJ
Kajander KC, Sahara Y, Iadarola MJ, Bennett GJ: Dynorphin increases in the dorsal spinal cord in rats with a painful peripheral neuropathy. Peptides 1990; 11:719–28Kajander, KC Sahara, Y Iadarola, MJ Bennett, GJ
Malan TP, Ossipov MH, Gardell LR, Ibrahim M, Bian D, Lai J, Porreca F: Extraterritorial neuropathic pain correlates with multisegmental elevation of spinal dynorphin in nerve-injured rats. Pain 2000; 86:185–94Malan, TP Ossipov, MH Gardell, LR Ibrahim, M Bian, D Lai, J Porreca, F
Hao J, Yu W, Wiesenfeld-Hallin Z, Xu XJ: Treatment of chronic allodynia in spinally injured rats: effects of intrathecal selective opioid receptor agonists. Pain 1998; 75:209–17Hao, J Yu, W Wiesenfeld-Hallin, Z Xu, XJ
Mika J, Przewlocki R, Przewlocka B: The role of delta-opioid receptor subtypes in neuropathic pain. Eur J Pharmacol 2001; 415:31–7Mika, J Przewlocki, R Przewlocka, B
Gomez-Flores R, Rice KC, Zhang X, Weber RJ: Increased tumor necrosis factor-alpha and nitric oxide production by rat macrophages following in vitro stimulation and intravenous administration of the delta-opioid agonist SNC 80. Life Sci 2001; 68:2675–84Gomez-Flores, R Rice, KC Zhang, X Weber, RJ
Brandt MR, Furness MS, Mello NK, Rice KC, Negus SS: Antinociceptive effects of delta-opioid agonists in rhesus monkeys: effects on chemically induced thermal hypersensitivity. J Pharmacol Exp Ther 2001; 296:939–46Brandt, MR Furness, MS Mello, NK Rice, KC Negus, SS
Sluka KA, Rohlwing JJ, Bussey RA, Eikenberry SA, Wilken JM: Chronic muscle pain induced by repeated acid injection is reversed by spinally administered mu- and delta-, but not kappa-, opioid receptor agonists. J Pharmacol Exp Ther 2002; 302:1146–50Sluka, KA Rohlwing, JJ Bussey, RA Eikenberry, SA Wilken, JM
Yaksh TL, Rudy TA: Chronic catheterization of the spinal subarachnoid space. Physiol Behavior 1976; 17:1031–6Yaksh, TL Rudy, TA
Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53:55–63Chaplan, SR Bach, FW Pogrel, JW Chung, JM Yaksh, TL
Long JB, Rigamonti DD, Oleshansky MA, Wingfield CP, Martinez-Arizala A: Dynorphin A-induced rat spinal cord injury: Evidence for excitatory amino acid involvement in a pharmacological model of ischemic spinal cord injury. J Pharmacol Exp Ther 1994; 269:358–66Long, JB Rigamonti, DD Oleshansky, MA Wingfield, CP Martinez-Arizala, A
Zhang J, Haddad GG, Xia Y: Delta-, but not mu- and kappa-opioid receptor activation protects neocortical neurons from glutamate-induced excitotoxic injury. Brain Res 2000; 885:143–53Zhang, J Haddad, GG Xia, Y
Wang XM, Mokha SS: Opioids modulates N  -methyl-d-aspartic acid (NMDA)-evoked responses of trigeminothalamic neurons. J Nuerophysiol 1996; 76:2093–6Wang, XM Mokha, SS
Suzuki T, Aoki T, Ohnishi O, Nagase H, Narita M: Different effects of NMDA/group I metabotropic glutamate receptor agents in delta- and mu-opioid receptor agonist-induced supraspinal antinociception. Eur J Pharmacol 2000; 396:23–8Suzuki, T Aoki, T Ohnishi, O Nagase, H Narita, M
Bharagava HN, Zhao GM: Effects of competitive and noncompetitive antagonists of the N  -methyl-d-aspartate receptor on the analgesic action of delta 1- and delta-2opioid receptor agonists in mice. Br J Pharmacol 1996; 119:1586–90Bharagava, HN Zhao, GM
Fig. 1. Time-response curves for tactile allodynia induced by intrathecal injections of dynorphin A (1-13). Saline, 0.9%,(group S; closed circle, n = 8), 0.25 nmol of dynorphin (group D0.25; triangle, n = 7), 1 nmol of dynorphin (group D1; square, n = 9), or 2 nmol of dynorphin (group D2; open circle, n = 7) was intrathecally administered and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
Fig. 1. Time-response curves for tactile allodynia induced by intrathecal injections of dynorphin A (1-13). Saline, 0.9%,(group S; closed circle, n = 8), 0.25 nmol of dynorphin (group D0.25; triangle, n = 7), 1 nmol of dynorphin (group D1; square, n = 9), or 2 nmol of dynorphin (group D2; open circle, n = 7) was intrathecally administered and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
Fig. 1. Time-response curves for tactile allodynia induced by intrathecal injections of dynorphin A (1-13). Saline, 0.9%,(group S; closed circle, n = 8), 0.25 nmol of dynorphin (group D0.25; triangle, n = 7), 1 nmol of dynorphin (group D1; square, n = 9), or 2 nmol of dynorphin (group D2; open circle, n = 7) was intrathecally administered and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
×
Fig. 2. Effect of MK801 on 2 nmol of dynorphin A (1-13)-induced tactile allodynia. Saline, 0.9%, (group S; circle, n = 7), 10 nmol of MK801 (group M10; triangle, n = 7), or 5 nmol of MK801(group M5; square, n = 7) was intrathecally administered 20 min before intrathecal injection of 2 nmol of dynorphin A (1-13), and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
Fig. 2. Effect of MK801 on 2 nmol of dynorphin A (1-13)-induced tactile allodynia. Saline, 0.9%, (group S; circle, n = 7), 10 nmol of MK801 (group M10; triangle, n = 7), or 5 nmol of MK801(group M5; square, n = 7) was intrathecally administered 20 min before intrathecal injection of 2 nmol of dynorphin A (1-13), and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
Fig. 2. Effect of MK801 on 2 nmol of dynorphin A (1-13)-induced tactile allodynia. Saline, 0.9%, (group S; circle, n = 7), 10 nmol of MK801 (group M10; triangle, n = 7), or 5 nmol of MK801(group M5; square, n = 7) was intrathecally administered 20 min before intrathecal injection of 2 nmol of dynorphin A (1-13), and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
×
Fig. 3. Effect of SNC80 on 2 nmol of dynorphin A (1-13)-induced tactile allodyniaSaline, 0.9%,with 100 mm HCl (group S; circle, n = 9) or 100 nmol of SNC80 (group S100; triangle, n = 9), or 25 nmol of SNC80 (group S25; square, n = 9) was intrathecally administered 20 min before intrathecal injection of 2 nmol of dynorphin, and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
Fig. 3. Effect of SNC80 on 2 nmol of dynorphin A (1-13)-induced tactile allodyniaSaline, 0.9%,with 100 mm HCl (group S; circle, n = 9) or 100 nmol of SNC80 (group S100; triangle, n = 9), or 25 nmol of SNC80 (group S25; square, n = 9) was intrathecally administered 20 min before intrathecal injection of 2 nmol of dynorphin, and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
Fig. 3. Effect of SNC80 on 2 nmol of dynorphin A (1-13)-induced tactile allodyniaSaline, 0.9%,with 100 mm HCl (group S; circle, n = 9) or 100 nmol of SNC80 (group S100; triangle, n = 9), or 25 nmol of SNC80 (group S25; square, n = 9) was intrathecally administered 20 min before intrathecal injection of 2 nmol of dynorphin, and paw withdrawal thresholds were assessed by using von Frey filaments. *  P  < 0.05  versus  control; †  P  < 0.05  versus  group S. Data are expressed as mean ± SEM. 
×